MedEsthetics

OCTOBER 23, 2023

The study in the Journal of the American Academy of Dermatology indicates that allergic contact dermatitis has similar symptoms and can be triggered by a range of substances, causing it to be underdiagnosed.

Dermatitis 113

Dermatitis Dermatology 113

Dermatology Times

MAY 13, 2025

Raj Chovatiya, MD, PhD, MSCI, discusses how IL-13 and IL-31 inhibitors represent distinct yet complementary mechanisms in the management of atopic dermatitis.

Dermatitis 53

Dermatitis Management 53

Dermatology Times

JUNE 26, 2025

An expert discusses how personalizing systemic atopic dermatitis treatment requires considering factors such as disease severity, patient impact, treatment failures, age, comorbidities, and patient preferences when selecting between biologics and JAK inhibitors.

Dermatitis 36

Dermatitis Treatments 36

Dermatology Times

JULY 10, 2025

Christopher Bunick, MD, PhD, highlights how dupilumab transforms atopic dermatitis treatment in children, improving health outcomes and quality of life beyond skin symptoms.

Dermatitis 36

Dermatitis Therapy Treatments 36

Dermatology Times

JULY 7, 2025

An expert discusses how a 5-year-old child with severe atopic dermatitis affecting sleep and school performance demonstrates the need for systemic therapy escalation, with dupilumab being an ideal choice given its efficacy for both atopic dermatitis and comorbid asthma.

Dermatitis 36

Dermatitis Therapy 36

West Lake Dermatology

JANUARY 23, 2025

Eyelid eczema, also known as eyelid dermatitis, is a skin condition that affects the delicate skin around the eyes. What is Eyelid Eczema (Eyelid Dermatitis)? What is Eyelid Eczema (Eyelid Dermatitis)? Atopic Dermatitis Atopic dermatitis is the most common form of eczema.

Eczema 36

Eczema Dermatitis Treatments Irritation 36

Dermatology Times

JUNE 28, 2025

effectively treats seborrheic dermatitis with minimal pigment changes. Dupilumab Maintains Long-Term Flare Control Across Dosing Regimens in Atopic Dermatitis A year-long study showed dupilumab alone effectively prevented flares in moderate to severe atopic dermatitis, with consistent safety across various dosing schedules.

Dermatology 72

Dermatology Dermatitis Eczema Rosacea 72

Dermatology Times

JULY 7, 2025

Further large-scale randomized controlled trials are needed to validate WBC's efficacy and safety in atopic dermatitis management. SHOW MORE Explore the potential of whole-body cryotherapy as a novel, non-pharmacologic treatment for managing atopic dermatitis symptoms effectively. Whole-body cryotherapy in atopic dermatitis.

Therapy 66

Therapy Eczema Dermatitis Rosacea 66

The Dermatology Digest

OCTOBER 29, 2024

Linda Stein Gold, MD, Director of Dermatology Clinical Research at Henry Ford Health System in Detroit, MI, reviews new data on atopic dermatitis (AD) patients who switched to lebrikizumab (Ebyglyss, Lilly) from dupilumab (Dupixent, Sanofi and Regeneron) that was presented at the 2024 Fall Clinical Dermatology Conference in Las Vegas, NV. “If

Dermatitis 78

Dermatitis Clinic Dermatology Treatments 78

Dermatology Times

JUNE 26, 2025

An expert discusses how atopic dermatitis creates significant physical and quality-of-life burdens affecting up to 20% of pediatric and 10% of adult patients globally, with presentations varying across age groups and key unmet needs including improved access to care and disease recognition across different skin tones.

Dermatitis 36

Dermatitis Clinic 36

Dermatology Times

JUNE 6, 2025

At RAD 2025, Mona Shahriari, MD, emphasized the cumulative life course impairment of AD in pediatric and adult patients, highlighting its impact on sleep, mental health, family well-being, and quality of life.

Dermatitis 71

Dermatitis 71

Dermatology Times

JUNE 10, 2025

At RAD 2025, Christopher Bunick, MD, PhD, presented data on amlitelimab and rocatinlimab, highlighting their potential to suppress cytokine signaling and more.

Dermatitis 88

Dermatitis 88

Dermatology Times

JUNE 7, 2025

Data presented at the 2025 RAD Conference shows dupilumab improves daily functioning, mental health, and social aspects in patients with atopic dermatitis.

Dermatitis 50

Dermatitis 50

Dermatology Times

JUNE 10, 2025

Image Credit: © DermNet The Revolutionizing Atopic Dermatitis (RAD) 2025 meeting in Nashville, Tennessee, showcased a wide range of innovations in the management of atopic dermatitis (AD). Notably, atopic dermatitis itself was the only adverse event leading to dose escalation in more than 1% of patients.

Eczema 67

Eczema Dermatitis Rosacea Safety 67

Dermatology Times

JUNE 7, 2025

SHOW MORE Eli Lilly revealed promising results for lebrikizumab in treating atopic dermatitis in patients with skin of color at the RAD 2025 conference. By week 24, 78.4% achieved EASI 75, and 54.1% reached IGA 0/1, with notable improvements in hyperpigmentation.

Eczema 74

Eczema Dermatitis Safety Rosacea 74

Dermatology Times

JUNE 17, 2025

Feser, a board-certified dermatologist based in Nashville and principal investigator at IC Research in Murfreesboro, Tennessee, emphasized that “HS is a really growing field,” pointing to a wave of clinical research that mirrors past surges in psoriasis and atopic dermatitis innovation. Subscribe Now!

Eczema 72

Eczema Rosacea Dermatitis Management 72

Dermatology Times

JUNE 28, 2025

A year-long study showed dupilumab alone effectively prevented flares in moderate to severe atopic dermatitis, with consistent safety across various dosing schedules.

Dermatitis 34

Dermatitis Safety 34

Dermatology Times

APRIL 25, 2025

Alexandra Golant, MD, discusses how advancements in pediatric atopic dermatitis (AD) treatment, including topical Janus kinase (JAK) inhibitors like ruxolitinib, may reshape guidelines, yet hurdles remain in regulatory approval, safety data, and accessibility. Adoption depends on efficacy, cost, insurance, and caregiver education.

Dermatitis 36

Dermatitis Treatments Therapy Safety 36

The Dermatology Digest

DECEMBER 24, 2024

He spoke on this topic at the 2024 Revolutionizing Atopic Dermatitis (RAD) Conference. Raj Chovatiya, MD, PhD, Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago, IL, reviews the latest efficacy and safety data on oral and topical Janus kinase (JAK) inhibitors used in dermatology.

Safety 74

Safety Dermatology Dermatitis Medical 74

Dermatology Times

JUNE 29, 2025

SHOW MORE Maria Hordinsky, MD, urges dermatology clinicians to consider allergic contact dermatitis when scarring alopecia treatments fail. Undiagnosed allergies to medication or injection components can stall patient progress, necessitating further investigation through testing.

Scarring 67

Scarring Clinic Eczema Rosacea 67

Dermatology Times

MAY 19, 2025

The study offers reassurance regarding the safety profile of JAKis in patients with severe atopic dermatitis, particularly concerning their impact on venous thromboembolic events.

Dermatitis 41

Dermatitis Safety 41

Dermatology Times

JUNE 17, 2025

Gonzalez, MD Key Takeaways The INTEGUMENT-INFANT trial investigates roflumilast 0.05% cream for infants with atopic dermatitis, addressing a critical treatment gap in those aged 3 to 24 months. Gonzalez, MD Author(s): Marie Bosslett, Assistant Editor , Mercedes E. Mercedes E. Subscribe Now!

Eczema 65

Eczema Dermatitis Rosacea Safety 65

Dermatology Times

JUNE 6, 2025

At RAD 2025, Jonathan Silverberg, MD, PhD, MPH, provided an in-depth look at the clinical integration of newly approved biologics nemolizumab and lebrikizumab in AD.

Dermatitis 67

Dermatitis Clinic 67

Dermatology Times

JULY 7, 2025

An expert discusses how a 55-year-old African American man’s case highlights challenges in diagnosing atopic dermatitis in skin of color, emphasizing the importance of recognizing different disease presentations and addressing postinflammatory hyperpigmentation concerns.

Dermatitis 36

Dermatitis Hyperpigmentation 36

Dermatology Times

JUNE 9, 2024

Jonathan Silverberg, MD, PhD, MPH, presented his tips for effectively treating atopic dermatitis without worsening autoimmune comorbidities.

Dermatitis 92

Dermatitis 92

Dermatology Times

MARCH 28, 2024

Today officially marks 7 years since the US FDA approved dupilumab for the treatment of atopic dermatitis. Here's a look back at its approval timeline and all it has accomplished in the dermatology world in the time since.

Dermatitis 88

Dermatitis Dermatology Treatments 88

Dermatology Times

MAY 13, 2025

Researchers reveal TRIV-509, a novel monoclonal antibody, shows promise in rapidly improving atopic dermatitis by restoring skin barrier integrity and reducing inflammation.

Dermatitis 41

Dermatitis 41

Dermatology Times

APRIL 5, 2024

Mark Lebwohl, MD, emphasizes the importance of considering various factors, including severity of itch and interference with sleep, when determining treatments for patients with atopic dermatitis, even with presentation may not include typical symptoms.

Dermatitis 87

Dermatitis Treatments 87

Dermatology Times

MAY 5, 2025

Christopher Bunick, MD, PhD, discusses the evolving role of OX40-targeted biologics in atopic dermatitis treatment ahead of the upcoming RAD conference.

Therapy 68

Therapy Dermatitis Treatments 68

The Dermatology Digest

JANUARY 2, 2025

One of the core missions of theInternational League of Dermatological Societies ( ILDS ) is to raise awareness about the burden of skin diseases across the globe.ILDS President Henry Lim, MD, theSenior Vice President of Academic Affairs at the Henry Ford Health System inDetroit, MI, discusses how ILDS atlases on psoriasis, vitiligo,hidradenitis suppurativa,and (..)

Dermatitis 74

Dermatitis Dermatology 74

Dermatology Times

MAY 12, 2025

Discover the latest advancements in pediatric atopic dermatitis care, featuring expert insights on innovative treatments and family-centered management strategies.

Dermatitis 41

Dermatitis Innovations Management Treatments 41

Dermatology Times

DECEMBER 6, 2024

A study using proteome-wide association techniques identified novel protein biomarkers for atopic dermatitis.

Dermatitis 81

Dermatitis 81

Dermatology Times

JUNE 10, 2024

David Rosmarin, MD, shares key points from phase 3 data of ruxolitinib for vitiligo, as well as highlights the potential for targeting the STAT pathway in upcoming atopic dermatitis therapeutics.

Dermatitis 85

Dermatitis 85

Dermatology Times

JUNE 28, 2025

Nemolizumab is associated with a low incidence of injection site reactions in the treatment of atopic dermatitis and prurigo nodularis. Efficacy and safety of nemolizumab in subjects with moderate-to-severe atopic dermatitis. ClinicalTrials.gov. Updated August 14, 2024.

Injections 61

Injections Eczema Dermatitis Rosacea 61

Dermatology Times

MAY 19, 2025

Christopher Bunick, MD, PhD, discusses key differences in AD biologics and challenges in achieving optimal treatment targets.

Dermatitis 62

Dermatitis Treatments 62

Dermatology Times

JUNE 11, 2025

At RAD 2025, Matthew Zirwas, MD, explored the distinct clinical profiles of IL-31 and IL-13 inhibitors, highlighting nemolizumab’s potential superiority for itch relief.

Dermatitis 65

Dermatitis Clinic 65

Dermatology Times

JUNE 29, 2025

Maria Hordinsky, MD: Early Clue in Scarring Alopecia May Change Clinical Approach Maria Hordinsky, MD, urges dermatology clinicians to consider allergic contact dermatitis when scarring alopecia treatments fail. To stay informed with the latest conference insights, subscribe to receive our eNewsletters.

Dermatology 63

Dermatology Eczema Rosacea Dermatitis 63